Clopidogrel Tablet, Film Coated
Product Images NDC 65862-357

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 65862-357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal error bar chart showing the effect of co-administering proton pump inhibitors (PPIs) on the active metabolite exposure (AUC) of Clopidogrel Bisulfate 75 mg. The chart compares four PPIs—Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg—relative to clopidogrel administered alone. The X-axis represents the change relative to clopidogrel alone, ranging from 0.4 to 1.4, with mean values and 90% confidence intervals displayed for each PPI.*

FDA Label Image

Package Label-principal Display Panel (75 mg Blister Carton (10 x 10 Unit-dose))

Packaging label for Clopidogrel Tablets, USP 75 mg film-coated tablets by Aurobindo Pharma Limited. The label indicates a package containing 100 unit-dose tablets (10 x 10). The NDC number 65862-357-10 is visible. The label includes instructions for pharmacists to dispense the medication guide separately and states the tablet contains 97.875 mg of clopidogrel bisulfate USP equivalent to 75 mg clopidogrel base.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph depicting cumulative event rates (%) over 12 months of follow-up for cardiovascular death, myocardial infarction, and stroke. Two lines compare placebo plus aspirin and clopidogrel bisulfate plus aspirin, showing lower event rates for clopidogrel bisulfate. Statistical significance is indicated (P=0.00009).*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

A forest plot chart showing hazard ratios with 95% confidence intervals comparing Clopidogrel Bisulfate to placebo across various patient subgroups, including age, gender, race, enzyme elevation, diabetes, prior myocardial infarction and stroke, and concurrent medication use. The chart visually presents the risk estimates favoring Clopidogrel Bisulfate or placebo with data points and confidence intervals for each subgroup analyzed.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A Kaplan-Meier survival curve chart comparing the percentage of deaths before first discharge over days since randomization (up to 28 days) between patients receiving Clopidogrel and placebo. The chart shows lower mortality with Clopidogrel (7.5%) compared to placebo (8.1%), indicating a 7% proportional risk reduction.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A line graph comparing the percentage of patients experiencing death, re-infarction, or stroke before first discharge over 28 days between placebo and Clopidogrel groups. The vertical axis shows the percentage with these events, and the horizontal axis shows days since randomization. The graph notes a 9% proportional risk reduction with Clopidogrel compared to placebo.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart showing odds ratios (99% confidence intervals) comparing Clopidogrel Bisulfate versus placebo across various subgroups. Subgroups include gender, age at entry, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent usage. The plot visually indicates whether each subgroup favors Clopidogrel Bisulfate or placebo based on odds ratio values.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph depicting the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up. Two lines represent outcomes for aspirin and clopidogrel bisulfate, with cumulative event rates increasing over time and a p-value of 0.045 indicating statistical significance in the comparison.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A forest plot comparing hazard ratios with 95% confidence intervals for Clopidogrel Bisulfate and Aspirin across qualifying conditions: stroke, myocardial infarction (MI), and peripheral artery disease (PAD), including overall results. The plot displays numbers and percentages of patients favoring each treatment along a horizontal axis from 0.6 to 1.3 hazard ratio.*

FDA Label Image

Package Label-principal Display Panel (75 mg (30 Tablets Bottle))

Label for Clopidogrel Tablets, USP 75 mg film-coated tablets from Aurobindo Pharma Limited. The label states the product contains 30 tablets and includes storage instructions, distributor information for Aurobindo Pharma USA, Inc., and indicates the tablets contain 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base. It is made in India and includes an NDC barcode.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel Bisulfate showing its molecular components, including a thiophene ring, chlorine-substituted phenyl group, and other characteristic atoms linked within the molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.